CTC Bio said Monday that it has completed its patent registration for their premature ejaculation treatment composition in Europe.
The Ministry of Food and Drug Safety (MFDS) approved the company’s composition in 2013. It is the only orally taken premature ejaculation treatment recognized by the ministry aside from Priligy, a medication from Johnson & Johnson.
Currently, the company sells its product domestically through DongA ST, Chong Kun Dang, Jeil Pharmaceuticals and JW Pharmaceuticals. The product has also completed patent registrations in Australia.
“Since the treatment for premature ejaculation is the first drug that applied for a change of applications in Korea, there were some skeptic views about registering for an international patent,” said Cho Ho-yeon 조호연, CEO of CTC Bio 씨티씨바이오. “However, with the patents registered in Europe and Australia, it has completely erased any controversies regarding the patent technology.”
The company is also developing a combination drug for premature ejaculation and erectile dysfunction, Cho added.
Currently, the drug has finished phase 2 clinical trials.
<© Korea Biomedical Review, All rights reserved.>